ACID BASE, ION DISORDERS, LITHISASIS

Autor: M. A. El-Shahawy, H. S. Rasmussen, P. T. Lavin, A. Yang, D. K. Packham, B. Singh, S. D. Roger, M. Fusaro, L. Dalle Carbonare, A. Dusso, M. V. Arcidiacono, S. Pasho, M. Gallieni, M. S. Ormanji, F. Korkes, R. Meca, L. C. Baia, R. R. Ferraz, I. P. Heilberg, I. Nistor, I. Bararu, M.-C. Apavaloaie, L. Voroneanu, M.-D. Donciu, E. V. Nagler, A. Covic, H.-W. Gil, S.-H. Park, S.-Y. Hong, B. Ponte, H. Alwan, M. Pruijm, D. Ackermann, I. Guessous, G. Ehret, F. Paccaud, M. Mohaupt, A. Pechere-Bertschi, M. Burnier, P.-Y. Martin, M. Bochud, V. Filiopoulos, D. Biblaki, N. Manolios, I. Karatzas, D. Arvanitis, D. Vlassopoulos, A. Altuntas, V. Kidir, S. Inal, S. Diker, N. Cil, H. Orhan, M. T. Sezer, M. Verdelho, N. Rodrigues, F. Ribeiro, W. Y. Qunibi, H. Azar, R. Ossman, M. Flamant, D. Chelala, P. Ria, A. Fabris, C. Branco, G. Gambaro, A. Lupo, J. Hao, L. Qiu, Y. Li, R. Li, X. Li, L. Chen, S. Verdesca, D. Cucchiari, M. Podesta, S. Badalamenti, N. M. H. Veldhuijzen, K. G. F. Gerritsen, W. H. Boer, A. C. Abrahams, F. Mangione, P. Albrizio, V. Sepe, P. Esposito, A. Manini, S. Muciaccia, A. Dal Canton

Publikováno v: Nephrology Dialysis Transplantation. 29:iii178-iii185

Introduction and Aims: Hyperkalaemia is a risk factor for mortality in patients with cardiovascular disease and chronic kidney disease (CKD) (Goyal, 2012; Torlen, 2012) and limits use of renin-angiotensin-aldosterone system inhibitors (RAASi) in thes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86225bf56856a38dfc250bb1583b2445
https://doi.org/10.1093/ndt/gfu150

Extended administration of erythropoiesis-stimulating agents for optimising the management of renal anaemia: what is the evidence?

Autor: S. D. Roger

Publikováno v: International Journal of Clinical Practice. 62:1413-1422

Summary Background: Erythropoiesis-stimulating agents (ESAs) have transformed the management of anaemia in patients with chronic kidney disease (CKD), reducing transfusion requirements and leading to improved quality of life. However, effective anaem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37a8a8f7b9595e808f8ea3410a36c1c3
https://doi.org/10.1111/j.1742-1241.2008.01846.x

Primary IgA nephropathy: natural history and factors of importance in the progression of renal impairment

Autor: L S, Ibels, A Z, Gyory, R J, Caterson, C A, Pollock, J F, Mahony, D A, Waugh, S D, Roger, S, Coulshed

Publikováno v: Kidney international. Supplement. 61

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6e6849028bcfd96c3c85d0097d5b1d90
https://pubmed.ncbi.nlm.nih.gov/9328970

Enhanced platelet reactivity with erythropoietin but not following transfusion in dialysis patients

Autor: S D, Roger, J, Piper, B, Tucker, A E, Raine, L R, Baker, I B, Kovacs

Publikováno v: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 8(3)

Although the haemostatic defects that occur in uraemia are complex, a major factor is the anaemia of renal failure. This may now be corrected by recombinant human erythropoietin (rHuEpo) therapy rather than by repeated blood transfusion. Platelet rea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5b8763e9068390e833ee9733124c2e3f
https://pubmed.ncbi.nlm.nih.gov/8385286

Effects of erythropoietin on blood pressure

Autor: A E, Raine, S D, Roger

Publikováno v: American journal of kidney diseases : the official journal of the National Kidney Foundation. 18(4 Suppl 1)

Increased blood pressure (BP) has been the most commonly reported side effect in trials of treatment of the anemia of chronic renal failure with recombinant human erythropoietin (rHuEPO). An increase in BP develops in one third of patients, in most c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1894850508a2fb76e4760b3ffd8422a2
https://pubmed.ncbi.nlm.nih.gov/1928084